Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Novartis
Novartis
Point looks to turn the tables on Novartis
EP Vantage
Wed, 04/26/23 - 09:55 am
Novartis
Point Biopharma
radiopharmaceuticals
Novartis, helped by cost cuts, raises full-year outlook
Reuters
Tue, 04/25/23 - 10:47 am
Novartis
earnings
Novartis strikes $425M deal with 3BP for FAP-targeting peptide technology
Medical Marketing and Media
Tue, 04/25/23 - 10:32 am
Novartis
3B Pharmaceuticals
FAP-targeting peptides
Novartis plant cleared to produce in-demand cancer drug
BioPharma Dive
Mon, 04/24/23 - 10:59 pm
Novartis
drug manufacturing
Pluvicto
New Jersey
cancer
radiopharmaceuticals
FDA again delays Daiichi's plans to challenge Astellas and Novartis for blood cancer market
Fierce Biotech
Fri, 04/21/23 - 10:08 am
Daiichi Sankyo
Astellas
Novartis
quizartinib
FDA
blood cancer
Big pharma holds steady on research spending
EP Vantage
Fri, 04/21/23 - 10:03 am
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals
Big pharma’s biggest spenders revealed: 2022 edition
EP Vantage
Fri, 04/21/23 - 10:00 am
M&A
R&D
AbbVie
AstraZeneca
Bristol Myers Squibb
Eli Lilly
GSK
JNJ
Merck
Novartis
Pfizer
Roche
Sanofi
AACR 2023 – Hippo makes a splash
EP Vantage
Wed, 04/19/23 - 10:07 am
Vivace Therapeutics
VT3989
AACR
Novartis
Sanofi
Ikena Oncology
Double whammy: Supreme Court slaps down separate bids from Novartis, Sanofi
Fierce Pharma
Tue, 04/18/23 - 09:58 am
legal
Supreme Court
Novartis
Gilenya
Sanofi
Viatris
EpiPens
In upcoming skin disease clash, doctors see Novartis' Cosentyx as an underdog
Fierce Pharma
Tue, 04/11/23 - 10:04 am
Novartis
Cosentyx
AbbVie
Humira
hidradenitis suppurativa
UCB Pharma
Gene therapy startup Vedere to close two years after launch
BioPharma Dive
Sun, 04/2/23 - 04:20 pm
Vedere Bio
Novartis
gene therapy
CHMP gives thumbs-up for Wegovy use in adolescents, along with nine new drug recommendations
Endpoints
Sun, 04/2/23 - 04:17 pm
EMA
Europe
CHMP
Wegovy
Novo Nordisk
Bimervax
TG Therapeutics
Eli Lilly
Bristol Myers Squibb
Novartis
AstraZeneca
Bicycle, Novartis Ink Oncology Deal Worth up to $1.7B
BioSpace
Tue, 03/28/23 - 11:30 am
Bicycle Therapeutics
Novartis
drug discovery
oncology
radioligand
Top 10 pharma R&D budgets in 2022
Fierce Biotech
Mon, 03/27/23 - 10:21 pm
R&D
Roche
JNJ
Merck
Pfizer
Novartis
AstraZeneca
Bristol Myers Squibb
Eli Lilly
Sanofi
AbbVie
Novartis' Kisqali cuts recurrence risk in early-stage breast cancer
BioSpace
Mon, 03/27/23 - 11:27 am
Novartis
clinical trials
Kisqali
breast cancer
FDA approves Pharming drug for ultra-rare immunodeficiency disease
Endpoints
Sun, 03/26/23 - 11:16 pm
FDA
Pharming
Novartis
leniolisib
APDS
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
CP Wire
Sun, 03/26/23 - 03:44 pm
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
Sun, 03/26/23 - 03:36 pm
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Novartis pulls the plug on UK-based cardiovascular study
Endpoints
Wed, 03/22/23 - 09:11 pm
Novartis
clinical trials
Leqvio
UK
Cardiovascular
Flare fires up with $123M series B to target transcription factors with 3 Big Pharmas in tow
Fierce Biotech
Wed, 03/22/23 - 10:13 am
Flare Therapeutics
funding
Pfizer
Eli Lilly
Novartis
transcription factors
Pages
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »